Kinaxis Announces Board Transitions and Management Update
Kinaxis® Inc. (“Kinaxis ” or the “Company ”) (TSX: KXS), a global leader in end-to-end supply chain orchestration, has, effective January 1, appointed Lynn Loewen to the Company’s Board of Directors and member of the Audit Committee. Due to current commitments, Betsy Rafael will not be seeking re-election to the Board at the 2025 annual general meeting.
“I’m pleased to add an exceptionally qualified Director in Lynn, who will ensure we maintain the strength of the audit oversight function, while bolstering the Board in a number of ways,” said Robert (Bob) Courteau, chair and interim chief executive officer. “Betsy has been an exceptional board member and we fully respect that she has several other professional and personal commitments that are taking her time. We appreciate her significant efforts and contributions and wish her the very best.”
Ms. Loewen is an accomplished business leader who has held several leadership positions, including at Bell Canada and Air Canada Jazz, as well as multiple directorship roles. She most recently was the President of Minogue Medical, where she also served as COO. Previously, Ms. Loewen served as president of Expertech Network Installation, vice president finance operations, vice president financial controls at Bell Canada, and vice president, Corporate Services and chief financial officer at Air Canada Jazz. She currently serves as a Director on the boards of the National Bank of Canada, where she is Audit Committee Chair, and Emera Inc., where she is a member of the Audit Committee. Ms. Loewen is the current Chancellor of Mount Allison University. She is a Fellow of the Chartered Professional Accountants and has received the Directors designation from the Institute of Corporate Directors. Ms. Loewen holds a Bachelor of Commerce from Mount Allison University.
As previously announced, after 30 years with Kinaxis, John Sicard has transitioned from CEO to a consultancy role effective January 1, 2025, and as such has stepped back from his board role. Courteau has stepped in as interim CEO and chair while the thorough search for Kinaxis’ next CEO continues apace. Sicard’s vacant board seat will be filled by the next permanent chief executive officer of the company.
“Much of the credit for Kinaxis being a leader in the supply chain orchestration space goes to John,” saidCourteau. “Our work together over the last several months has confirmed his commitment to the company and I am thrilled that John will be with us as a key advisor throughout as we work to scale the company in 2025. With John as advisor, Mark Morgan, our new president of Commercial Operations, and the full management team, we will continue to collaborate and ensure a smooth transition as I take on the interim CEO title. This group will provide continuity while we secure a new CEO who will guide us into the next stage of growth and beyond.”
About Kinaxis
Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them, in service of humanity. Our powerful, AI-infused supply chain orchestration platform, Maestro™ combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
Cautionary Note and Forward-Looking Information
This press release contains forward-looking information within the meaning of Canadian securities legislation. Forward-looking information relates to future events or the anticipated performance of Kinaxis and reflects management’s expectations or beliefs regarding such future events. In certain cases, statements that contain forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes” or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, or “will be taken”, “occur” or “be achieved” or the negative of these words or comparable terminology. Forward looking information in this press release includes statements with respect to the Company’s anticipated permanent CEO and growth plans. By its very nature forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual performance of Kinaxis to be materially different from any anticipated performance expressed or implied by such forward-looking information.
Forward-looking information is subject to a variety of risks and uncertainties, which could cause actual events or results to differ from those reflected in the forward-looking information, including, without limitation, the risks described under the heading “Risk Factors” in the Company’s annual information form dated March 25, 2024 for its fiscal year ended December 31, 2023 and other risks identified in the Company’s filings with Canadian securities regulators, which filings are available on SEDAR+ at https://www.sedarplus.ca.
The risk factors referred to above are not an exhaustive list of the factors that may affect any of the Company’s forward-looking information. Forward-looking information includes statements about the future and is inherently uncertain, and the Company’s actual achievements or other future events or conditions may differ materially from those reflected in the forward-looking information due to a variety of risks, uncertainties and other factors. The Company’s statements containing forward-looking information are based on the beliefs, expectations, and opinions of management on the date the statements are made, and the Company does not assume any obligation to update such forward-looking information if circumstances or management's beliefs, expectations or opinions should change, other than as required by applicable law. For the reasons set forth above, one should not place undue reliance on forward-looking information.
Source: Kinaxis Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250102516424/en/
Contacts
Media Relations
Belinda Thomas | Kinaxis
bthomas@kinaxis.com
+1 613-322-9305
Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
613-907-7613
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Perma-Pipe International Holdings, Inc. Announces $43 Million Contract Award in the Middle East Region10.1.2025 16:23:00 EET | Press release
Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) today announced it has received a formal letter of award for a development project located in the GCC region. Perma-Pipe will provide thermal insulation, anti-corrosion coatings, and other services from its Abu Dhabi facility. Project commencement is expected to begin in the third quarter of 2025. The value of this project is estimated to exceed $43 million. This project will utilize Perma-Pipe’s anti-corrosion coatings capabilities, fabrication, and the TRACE-THERM® insulation system, a spray-applied polyurethane foam jacketed with a high-density polyethylene casing. Saleh Sagr, Sr. Vice President for Perma-Pipe’s MENA region, commented, “This award follows the successful execution of numerous development projects in the region. Our differentiated coating solutions have proven to be well-suited for technically challenging projects. We would like to thank our customers for this significant award.” David Mansfield, President and CEO
Lenovo Integrates AI and Robotics to Deliver Smarter Retail Solutions10.1.2025 16:00:00 EET | Press release
Lenovo today introduced three new retail solutions that combine the best of robotics and artificial intelligence technologies. Premiering at NRF 2025 in New York City, each solution has been field-tested and proven in commercial settings. Lenovo Retail Content Management Services enables retailers to create, schedule and display digital content across screens store-wide, streamlining multimedia content management and enabling real-time updates and targeted messaging to drive awareness, interest and incremental sales. The complete solution comprises all hardware and software needed, and can be deployed, maintained and managed across multiple locations globally. A leading food and beverage chain has deployed this content management service across 100+ stores and achieved substantial cost savings from dynamically managed promotional campaigns, reduced use of paper marketing materials, and reduced manpower needed to manage both campaigns and devices. Lenovo Retail Robotics with Yunji offer
Institute of Molecular and Clinical Ophthalmology Basel Spinout RhyGaze Closes USD 86 Million Series A Round to Further Novel Gene Therapy for Vision Restoration10.1.2025 15:00:00 EET | Press release
RhyGaze, a biotechnology company based in Basel, Switzerland and Philadelphia, Pa., USA, today announced that it has secured a Series A financing of USD 86 million. The round was led by GV (Google Ventures), alongside Arch Venture Partners, F-Prime Capital and founding investors BioGeneration Ventures and Novartis Venture Fund, who contributed USD 11 million to an earlier seed round. RhyGaze was founded on intellectual property exclusively licensed to the company by the Institute of Molecular and Clinical Ophthalmology Basel (IOB), a scientific institute led by Director Botond Roska, M.D., Ph.D., who is a scientific co-founder of RhyGaze. This funding will enable further development of RhyGaze’s lead clinical candidate, a novel gene therapy for optogenetic vision restoration in diseases causing blindness. Activities to be supported include formal pharmacology and toxicology testing, a non-interventional, observational study to assess potential clinical endpoints in patient groups eligi
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore10.1.2025 14:30:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) with best-in-class potential being studied for the treatment of Immunoglobulin A nephropathy (IgAN) and other B cell-mediated diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250110168811/en/ Under the terms of the agreement, Vertex will receive an upfront payment, as well as certain regulatory milestone payments and tiered royalties, on net sales of pove in the region of focus for Zai Lab. Zai Lab will utilize its extensive research and deve
Compass Pathways Announces Pricing of Underwritten Offering10.1.2025 14:01:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares (“ADSs”) and in lieu of ADS, to certain institutional investors, pre-funded warrants to purchase up to 11,044,720 ADSs. Each ADS and pre-funded warrant shall be accompanied by a warrant (“ADS Warrant”) to purchase one ADS, which has an exercise price of $5.796 per ADS, representing a 40% premium to the last sale price and will be exercisable following a specified data milestone. The offering price is $4.275 per ADS and accompanying ADS Warrant, and $4.2649 per pre-funded warrant and accompanying ADS Warrant. All of the securities are to be sold by Compass. The offering is expected to close on or about January 13, 2025, subject to satisfaction of customary closing conditions. The offering was led by Deep Track Capital and included participation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom